@article{fc9b2c900bf34c8fa77daee4fff5adda,
title = "PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure: HFpEF Eligibility for PARAGON-HF",
author = "Sabina Sayeed and Marat Fudim and Devore, {Adam D.} and Haolin Xu and Matsouaka, {Roland A.} and Heidenreich, {Paul A.} and Yancy, {Clyde W.} and Fonarow, {Gregg C.} and Hernandez, {Adrian F.}",
note = "Funding Information: Funding: M. Fudim is supported by an American Heart Association Grant 17MCPRP33460225 and NIH T32 Grant 5T32HL007101. Funding Information: The Get With The Guidelines{\textregistered}-Heart Failure (GWTG-HF) program is provided by the American Heart Association. GWTG-HF is sponsored, in part, by Amgen Cardiovascular and has been funded in the past through support from Medtronic, GlaxoSmithKline, Ortho-McNeil, and the American Heart Association Pharmaceutical Roundtable. Powered by IQVIA, Cambridge, MA. Duke Clinical Research Institute (DCRI) served as the data analysis center.",
year = "2019",
month = dec,
doi = "10.1016/j.cardfail.2019.10.003",
language = "English (US)",
volume = "25",
pages = "1009--1011",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "12",
}